Clinical Trials Using Axitinib

Clinical trials are research studies that involve people. The clinical trials on this list are studying Axitinib. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-10 of 10
  • Axitinib and Nivolumab in Treating Patients with Unresectable or Metastatic TFE / Translocation Renal Cell Carcinoma

    This phase II trial studies how well axitinib and nivolumab works in treating patients with TFE / translocation renal cell carcinoma that cannot be removed by surgery or has spread to other places in the body. Axitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving axitinib and nivolumab may work better in treating patients with TFE / translocation renal cell carcinoma compared to standard treatment, including surgery, chemotherapy, or immunotherapy.
    Location: 215 locations

  • Axitinib with or without Anti-OX40 Antibody PF-04518600 in Treating Patients with Metastatic Kidney Cancer

    This randomized phase II trial studies how well axitinib with or without anti-OX40 antibody PF-04518600 work in treating patients with kidney cancer that has spread to other parts of the body. Axitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Biological therapies, such as anti-OX40 antibody PF-04518600, use substances made from living organisms that may stimulate the immune system in different ways and stop tumor cells from growing. Giving axitinib with or without anti-OX40 antibody PF-04518600 may work better in treating patients with kidney cancer.
    Location: 9 locations

  • Axitinib and Nivolumab in Treating Patients with Advanced Kidney Cancer

    This phase I / II trial studies the side effects and best dose of axitinib when given together with nivolumab and to see how well they work in treating patients with kidney cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment. Axitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving axitinib together with nivolumab may work better in treating patients with advanced kidney cancer.
    Location: 3 locations

  • Axitinib and Avelumab in Treating Patients with Recurrent or Metastatic Adenoid Cystic Carcinoma

    This phase II trial studies how well axitinib and avelumab work in treating patients with adenoid cystic carcinoma that has come back or spread to other places in the body. Axitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as avelumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving axitinib and avelumab together may help to control adenoid cystic carcinoma.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Axitinib in Treating Patients with Metastatic, Recurrent, or Primary Unresectable Pheochromocytoma or Paraganglioma

    This phase II trial studies how well axitinib works in treating patients with pheochromocytoma or paraganglioma that has spread to other parts of the body (metastatic), has come back (recurrent), or cannot be removed by surgery (refractory). Axitinib may stop the growth or shrink tumor cells by blocking some of the enzymes needed for cell growth.
    Location: NYP / Columbia University Medical Center / Herbert Irving Comprehensive Cancer Center, New York, New York

  • Axitinib before Surgery in Treating Participants with Localized Clear Cell Kidney Cancer

    This phase II trial studies how well axitinib works before surgery in treating participants with clear cell kidney cancer that has not spread to other parts of the body. Axitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving axitinib before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.
    Location: University of California San Diego, San Diego, California

  • Survival Prolongation by Rationale Innovative Genomics

    Patients with advanced / metastatic non-small cell lung cancer (NSCLC) with no documented targetable alterations (Epidermal Growth Factor Receptor (EGFR) mutation, Anaplastic Lymphoma Kinase (ALK) translocation, ROS1 mutation if available or MET exon 14 skipping mutation if available) will receive a tri-therapy associating avelumab, axitinib and palbociclib.
    Location: University of California San Diego, San Diego, California

  • Axitinib in Treating Patients with Recurrent or Metastatic Head and Neck Cancer That Cannot Be Removed by Surgery

    This phase II trial studies the best dose of axitinib and how well it works in treating patients with head and neck cancer that has come back, spread from where it started to other places in the body, or cannot be removed by surgery. Axitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan

  • Axitinib and L-Selenomethionine in Treating Patients with Previously Treated Advanced Metastatic Clear Cell Renal Cell Carcinoma

    This phase I trial studies the side effects and best dose of L-selenomethionine when given together with axitinib in treating patients with clear cell renal cell carcinoma that has spread from the primary site (place where it started) to other places in the body and usually cannot be cured or controlled with treatment (advanced metastatic). L-selenomethionine may stop the growth of tumor cells by blocking the growth of new blood vessels necessary for tumor growth. Axitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving L-selenomethionine together with axitinib may be a better treatment for advanced metastatic clear cell renal cell carcinoma
    Location: University of Iowa / Holden Comprehensive Cancer Center, Iowa City, Iowa

  • Continuing Access to Axitinib (A406- AG- 013736 ) For Patients Previously Receiving AG 013736 In Clinical Trials

    To allow continuation of axitinib (AG 013736) treatment to patients experiencing clinical benefit in a closing axitinib trial
    Location: See Clinical Trials.gov